meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - HR positive
es-BC - HR positive - (neo)adjuvant (NA)
2
es-BC - HR-positive - 1st line (L1)
1
la/mBC - HR positive
2
la/mBC - HR positive - (neo)adjuvant (NA)
3
la/mBC - HR positive - NA - PIK3CA mutant
la/mBC - HR-positive - 1st line (L1)
13
la/mBC - HR positive - L1 - PIK3CA mutant
1
la/mBC - HR-positive - 2nd line (L2)
20
la/mBC - HR positive - L2 - all population
1
la/mBC - HR positive - L2 - PIK3CA mutant
1
phosphoinositide 3-kinase (PI3K) inhibitor
alpelisib based treatment
alpelisib plus letrozole
buparlisib based treatment
buparlisib plus letrozole
versus all
vs endocrine therapy
vs letrozole
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
alpelisib based treatment
alpelisib plus letrozole
la/mBC - HR positive - (neo)adjuvant (NA)
3
la/mBC - HR positive - NA - PIK3CA mutant
Comparator:
vs letrozole;
Risk of bias:
low;
some concerns;
high;
NA;